Systemic administration of chemotherapeutic agents results in indiscriminate drug distribution and severe toxicity. Here we report a technology potentially overcoming these shortcomings through encapsulation and cancer cell-specific targeting of chemotherapeutics in bacterially derived 400 nm minicells. We discovered that minicells can be packaged with therapeutically significant concentrations of chemotherapeutics of differing charge, hydrophobicity, and solubility. Targeting of minicells via bispecific antibodies to receptors on cancer cell membranes results in endocytosis, intracellular degradation, and drug release. This affects highly significant tumor growth inhibition and regression in mouse xenografts and case studies of lymphoma in dogs despite administration of minute amounts of drug and antibody; a factor critical for limiting systemic toxicity that should allow the use of complex regimens of combination chemotherapy.
INTRODUCTION
Severe toxicity remains a major factor limiting cancer chemotherapeutics. Lack of cancer cell specificity, indiscriminate drug distribution, and rapid clearance necessitate frequent administration of high doses of chemotherapeutics to elicit a satisfactory clinical response (Langer, 1998) . Anticancer antibodies directed to overexpressed receptors on cancer cells, such as the epidermal growth factor receptor (EGFR; Nicholson et al., 2001 ) and HER2/ neu (Rae and Lippman, 2004) , are less toxic but do not possess the potency and wide spectrum antitumor activity of chemotherapeutic drugs. Efforts are being made to develop targeted drug delivery systems (DDSs), such as stealth liposomes (Medina et al., 2004) , nanoparticles (Brannon-Peppas and Blanchette, 2004; Ferrari, 2005) , and polymer therapeutics (Duncan, 2003) , which encapsulate the cytotoxic drug in a vehicle and target it to cancer cells via tumor cell-surface receptors. However, these technologies are also hampered by shortcomings, such as drug leakage in vivo, lack of versatility in terms of packaging a diverse range of different drugs without significant derivatization, thereby reducing drug potency, and difficulties in production scale-up, particularly for nanoparticles.
Here we show that bacterial minicells which are anucleate nanoparticles produced as a result of inactivating SIGNIFICANCE Nontargeted cancer chemotherapy is currently associated with severe toxicity. This report describes bacterially derived nano-sized particles (minicells) for encapsulation of a range of different chemotherapeutic drugs and specifically targeting the minicells to tumor cell-surface receptors via bispecific antibodies coating the minicells. Receptor engagement results in minicell endocytosis, intracellular degradation, and drug release. Consequently, highly significant tumor growth inhibition and regression is achieved despite administration of minute amounts of drug and antibody. The dramatic increase in therapeutic index may permit the use of multidrug combinations to achieve an improved outcome for cancer therapy. (B) Minicell purification using sequential density gradient centrifugation steps (Ba-Bc) on OptiPrep (6%-20% gradients) showing progressive separation and elimination of parental bacteria from the crude minicell preparation (Ba), resulting in significant purification by the third step (Bc). (C) Fluorescence microscopy images showing differences in size between native E. coli minCDE-strain grown in the absence of NaCl (Ca), and filamentous forms stained with LIVE/DEAD Baclight bacterial viability kit (Molecular Probes; green [live] , red [dead] fluorescence) resulting from growth in 5% NaCl (Cb) . Scale bar, 20 mm. (D) Minicell and bacterial counts during the various steps of minicell purification. (Da) overnight culture, (Db) differential centrifugation, (Dc) 0.45 mm crossflow filtration, (Dd-Df) successive OptiPrep gradients, (Dg) 2 hr activation of residual bacteria in TSB, (Dh) 2 hr incubation in TSB/5% NaCl, (Di) antibiotic treatment, (Dj) buffer exchange, (Dk) 0.45 mm dead-end filtration, (Dl) antiendotoxin treatment. Each value is a mean of three samples collected from a separate purification process. Error bars; ± SEM. (E) Minicells packaged with Dox, showing red autofluorescence of the drug (Ea), or green fluorescence after loading with either BODIPY FL-conjugated vinblastine (Eb), or Oregon Green 488-conjugated Pac (Ec) . No autofluorescence was observed with empty minicells (data not shown). Scale bar, 5 mm. (F) Fluorescent images showing BsAb bound to and coating the surface of drug-packaged minicells. Alexa Fluor 488-conjugated BsAb (green fluorescence) bound to minicells Dox and imaged to show only the green fluorescence of the BsAb (Fa), or to show both the green fluorescent BsAbs, and the genes that control normal bacterial cell division (De Boer et al., 1989; Lutkenhaus and Addinall, 1997; Ma et al., 2004) , thereby derepressing polar sites of cell fission, may provide a solution to these and other obstacles to cytotoxic drug delivery.
RESULTS
Minicell Generation, Characterization, and Purification Genetically defined minCDEÀ chromosomal deletion mutants were generated from Salmonella enterica serovar Typhimurium (S. Typhimurium), Escherichia coli, Shigella flexneri, Pseudomonas aeruginosa (GramÀ), and Listeria monocytogenes (Gram+) strains. All mutants yielded large numbers of minicells with a uniform diameter of 400 ± 20 nm ( Figure 1A ). Like parental bacteria, minicells from GramÀ bacteria have a ruffled surface (Figures 1Ac-1Ae ) characteristic of their lipopolysaccharide (LPS) coat. By contrast, those from L. monocytogenes have the rigid cell-wall structure (Figure 1Af ) expected of a Gram+ bacterial cell wall. That minicells are derived from their respective parental bacteria is evident, for example, by the ability to immunogold label S. Typhimurium minicells using an anti-S. Typhimurium O-antigen MAb (Figure 1Ab ).
Complete and reproducible purification of minicells was achieved using a procedure to eliminate contaminants such as parent bacterial cells, cellular debris, intracellular components, free nucleic acids, and free endotoxin. Initial centrifugation and crossflow filtration steps ( Figure 1B ) resulted in >90% elimination of bacterial cells. However, some bacterial cells permeated the filter pores irrespective of how many serial crossflow filtrations were performed. This was presumably due to some bacterial cells striking the filter surface perpendicularly and, thus, passing through it, since the transverse diameter of parent and minicells is the same, being 400 nm. To eliminate residual bacterial cells, we took advantage of the fact that under stress-inducing conditions, such as growth in high salt, septum formation is incomplete during bacterial cell division, resulting in filament formation (Mattick et al., 2000) . As shown in Figure 1C , incubation in the presence of 5% NaCl for 4 hr reliably converted parent bacteria into filaments of various lengths. This step was thus incorporated after the initial 0.45 mm crossflow filtration steps and the resulting filtrate was subjected to 0.2 mm crossflow filtration to remove small contaminants like bacterial membrane blebs, intracellular components, cellular debris, free nucleic acids, and endotoxin. These pass through the 0.2 mm filter, but minicells and residual bacterial cells are retained. The retentate was then filtered through a 0.45 mm dead-end filter and both the filtrate and retentate were subjected to FACS analysis. This revealed that filaments were only present in the retentate and, thus, were entirely eliminated from the filtrate. As a result, the final minicell preparation was sterile as confirmed by plating the entire preparation on growth agar plates and incubating it overnight at 37 C to demonstrate the absence of bacterial colonies. Additionally, preparations were grown for 14 days in thioglycolate broth to demonstrate the absence of any slow-growing organisms. Minicells were enumerated by FACS analysis, with a yield of approximately 5 3 10 10 to 10 11 minicells ( Figure 1D ) from a 6 L starting culture being routinely obtained. We also demonstrated that minicells can be lyophilized in a cryoprotectant and stored for at least 4 months (the longest period tested) and then successfully reconstituted (data not shown).
Efficient Packaging of Chemotherapeutic Drugs into Minicells, Drug Quantitation, and Targeting Using Bispecific Antibodies To determine if minicells can be packaged with chemotherapeutic drugs down a concentration gradient despite an intact bilayer membrane, preparations of purified minicells (10 9 ) derived from S. Typhimurium and E. coli minCDEÀ mutants were separately incubated with the chemotherapeutic drugs, doxorubicin (Dox; 60 mg/ml), Oregon Green 488-conjugated paclitaxel (Pac; 100 mg/ml), and BODIPY FL-conjugated vinblastine (Vin; 100 mg/ml). Minicell drug loading was evident with all drugs, either by the red autofluorescence of Dox (Figure 1Ea ) or green fluorescence of the minicells packaged with vinblastine or paclitaxel (Figures 1Eb and 1Ec) . Targeting of minicells was achieved using bispecific antibodies (BsAb), in which one arm recognizes the O-antigen component of the minicell surface LPS and the other, a cell-surface receptor specific for the mammalian cell to be targeted, for example, EGFR (El-Rayes and LoRusso, 2004) or HER2/neu receptor (Slamon et al., 1987) on breast and ovarian cancer cells, respectively. Linkage of these two antibodies via their Fc regions was achieved by the use of protein A/G. Drug loading and BsAb linkage were confirmed as shown in Figures 1E and 1F . Drug-packaged and targeted minicells were designated EGFR minicells Dox , for example, for those packaged with Dox and targeted using an anti-EGFR BsAb, or HER2 minicells Pac , for those packaged with Pac and targeted using an anti-HER2 BsAb. In additional studies, we found that minicells could also be packaged with other chemotherapeutic drugs, including carboplatin, cisplatin 5-fluorouracil (5-FU), gemcitabine, irinotecan, and kinesin spindle protein inhibitor monastrol. To determine the kinetics of minicell drug packaging, the amount of drug packaged per minicell in response to varying concentrations of drug in the incubation solution or varying times of incubation were evaluated. As shown in Figure 2A , drug packaging was dependent on, and directly A) Quantitation of minicell loading when incubated in the presence of different drug concentrations (Aa, Ac, and Ad) and for different times (Ab). In (Aa, Ac, and Ad), minicells were incubated for 1 hr with different concentrations of Dox, Pac, or cisplatin. Drug loading was determined after extraction from minicells and quantitation by HPLC and fluorescence detection or LC-MS/MS. In (Ab), minicells were incubated with Dox (60 mg/ml) for the times shown (n = 6). To evaluate drug efflux after loading, minicells were incubated in an external concentration of Dox (200 mg/ml). The minicells Dox were incubated in BSG for 72 hr at 4 C and Dox was extracted and quantitated from samples (triplicate) at the time points shown (Ae). Despite prolonged incubation in BSG no drug efflux was observed. Error bars, ± SEM. (B) Phagocytic uptake of nontargeted minicells by macrophages. S. Typhimurium-derived minicells were incubated with mouse macrophage cells (RWA 264.7) at a ratio of 100:1. At the times indicated, the cells were subjected to immunogold labeling using anti-O-antigen primary, and gold (10 nm)-conjugated anti-mouse secondary antibody followed by TEM. Immunogold-labeled minicells are evident on the macrophage cell surface (Ba). At later times numerous minicells can be seen within intracellular vacuoles (Bb and Bc) where disruption of their cell walls is evident. Scale bar, 500 nm. related to, both the drug concentration in the incubation solution (Figures 2Aa, 2Ac, and 2Ad) , and the time of incubation ( Figure 2Ab ). With the incubation of 5 3 10 8 minicells for 1 hr with 250 mg/ml Dox, 100 mg/ml Pac, or 400 mg/ml cisplatin, the amount packaged was $4.8 mg, 0.25 mg, and 0.1 mg, respectively. This equates to $10 million, 220,000, and 614,000 drug molecules packaged per minicell, respectively. To examine drug efflux, minicells Dox were incubated for up to 72 hr in buffered saline gelatin (BSG) before drug extraction and quantitation. This confirmed a lack of drug efflux ( Figure 2Ae ). These findings therefore show that minicells can be readily packaged with chemotherapeutic drugs, whether they be hydrophilic (irinotecan), hydrophobic (Pac, cisplatin, carboplatin, monastrol), or amphipathic (Dox, vinblastine, , and that diffusion across the minicell phospholipid bilayermembrane is essentially unidirectional; efflux not being observed even with extensive minicell washing and incubation in drug-free solution.
Intracellular Processing of Minicells and Targeted
Minicell-Mediated Drug Delivery to Cancer Cells In Vitro Following internalization, TEM studies of minicell-treated cancer cells and mouse macrophage cells showed that the minicells were localized in intracellular vacuoles ( Figure 2B ). As many as five to eight minicells were localized in a single vacuole, with a single cell carrying as many as 40 to 50 minicells. At later time points, minicell integrity was lost and membrane fragments carrying LPS were evident within vacuoles, indicating minicell breakdown ( Figure 2Bc ). To determine if BsAb-targeted, drug-packaged minicells can deliver bioactive drug intracellularly into human cancer cells, we incubated MDA-MB-468 human breast adenocarcinoma cells with EGFR minicells Dox (10 9 ), and monitored their fate over 48 hr by confocal microscopy. As controls, CMV minicells Dox where the BsAb is directed to an irrelevant antigen, CMV (cytomegalovirus capsid protein), and non-Dox-packaged EGFR minicells, were also studied.
As shown in Figure 3A , within 4 hr, only MDA cells treated with EGFR minicells Dox and EGFR minicells showed large numbers of minicells intracellularly (green fluorescence due to BsAb attached to the minicell surface; Figures 3Ab and 3Am ). Since the nontargeted minicells and CMV minicells Dox did not adhere to the MDA cell surface and were not internalized (absence of green or red fluorescence; Figure 3Ak ), it is likely that the BsAbtargeted EGFR minicells Dox and EGFR minicells gained entry into the MDA cell cytoplasm via EGFR-mediated endocytosis. At 4 hr, the minicells were confined to the MDA cell cytoplasm since the overlaid image (Figure 3Ae ) showed that the nucleus remained blue, similar to the DAPIstained nucleus seen in Figure 3Ad . Additionally, in the overlaid image (Figure 3Ae ), colocalization of the minicelland Dox-associated green and red fluorescence, respectively, showed yellow fluorescence in the MDA cell cytoplasm suggesting that the drug had not yet been released from the minicells. In contrast, by 16 hr to 24 hr, the MDA nucleus showed intense diffuse red fluorescence ( Figure 3B ). Cytotoxicity of minicell-delivered Dox was also apparent when cell viability was evaluated quantitatively using the colorimetric MTT assay (Cory et al., 1991) . Cell death was similar for MDA cells incubated with EGFR minicells Dox or free Dox, whereas viability remained largely unchanged when cells were treated with nontargeted minicells Dox ( Figure 3C ).
BsAb-Targeted, Minicell-Mediated Chemotherapeutic Drug Delivery to Human Breast, Leukemia, and Ovarian Cancer Cell Xenografts In Vivo We next investigated if receptor-targeted, drug-packaged minicells could deliver Dox to human cancer xenografts in vivo. As shown in Figure 4A , compared to control groups that received intravenous (i.v.) or intratumoral (i.t.) nontargeted minicells Dox, or BsAb (anti-O antigen/anti-EGFR) plus free Dox, administration of EGFR minicells Dox to mice with MDA xenografts (tumor volume $50-70 mmrest of the study. An additional beneficial effect of Dox delivery via targeted minicells is the markedly smaller amounts of drug required to affect tumor growth inhibition/regression with minicell-packaged delivery versus free drug administration. Thus, even $1875 times the amount of free Dox (150 mg) versus minicell-packaged Dox (0.08 mg) did not produce comparable xenograft growth inhibition (see for example Figure 4A , day 63, G2, G3, or G4 versus G7 or G8). Finally, phlebitis, thought to result from extravasation of drug and leading to local site vesicant/tissue damage, a well-recognized complication of i.v. Dox (Ewesuedo and Ratain, 2003) and one that was clearly evident in animals treated here with free drug ( Figure 4E ), was not observed in any of the mice treated with minicells Dox . We investigated if a hydrophobic drug like Pac could also be delivered effectively to mice with MDA xenografts by repeating the studies shown in Figure 4A , except using EGFR minicells Pac as the experimental treatment. Similar highly significant inhibition of tumor growth ( Figure 4B , p < 0.0003 and p < 0.0006 for the G7 and G8 groups versus all others, respectively) was evident both in mice treated i.v. or i.t. with EGFR minicells Pac . This was despite an $8000-fold lower Pac dose being administered via EGFR minicells Pac ($0.05 mg/mouse) compared to free Pac ($400 mg/mouse). Moreover, none of the mice treated with either EGFR minicells Dox or EGFR minicells Pac showed signs of toxicity, such as weight loss, fever, lethargy, loss of appetite, or death.
To investigate if specific targeting of tumor cells via BsAb-coated, drug-packaged minicells was essential for the observed antitumor effects, xenografts were established using A549 lung carcinoma cells that overexpress EGFR ($448,000/cell) but not the plasma membrane marker, CD33 ( Figure 4C ). These mice were given a range of control treatments ( Figure 4D ; G1 to G10 mice) and two experimental treatments with EGFR minicells Pac (G11) and CD33 minicells Pac (G12). Consistent with an essential role of the targeting BsAb, CD33 minicells Pac had no antitumor effect, whereas EGFR minicells Pac were highly effective in sulted in rapid and highly significant tumor regression (p < 0.001 for tumor volume at day 69 versus day 63).
(B) The studies were performed as detailed in Figure 4A , except that the animals were given either minicells packaged with Pac (0.05 mg/dose) or free Pac (20 mg/gm, $400 mg/mouse). Inhibition of tumor growth is evident by day 25 in the groups receiving EGFR minicells Pac (p < 0.0004 for tumor volume versus all other treatments), but not in the other groups.
(C) Receptor quantitation study on A549 lung carcinoma cell line where EGFR, HER-2/neu, and CD33 were quantitated. As negative controls, anti-CMV MAb was used along with untreated cells. Cells were treated with the various primary antibodies and a Phycoerythrin (PE)-labeled secondary antibody followed by FACS analysis. Receptor quantitation was carried out using the Quantum PE MESF kit (Molecules of Equivalent Soluble Fluorochrome; Bang Labs). Mean receptor numbers were EGFR ($447,515) and HER2 ($1686 for 50% cells and $917,352 for the remaining 50%). The cells did not stain for CD33 or CMV.
(D) A549 xenograft with a range of different controls including free Pac (G2), specifically and nonspecifically targeted BsAbs followed by free Pac (G3 and G4), nontargeted, Pac-packaged minicells (G5), nontargeted minicells followed by free Pac (G6), EGFR-targeted minicells (G7) and followed by free Pac (G8), nonspecifically targeted minicells (G9) and followed by free Pac (G10) as shown in the figure. The experimental groups consisted of EGFR minicells Pac (G11; A549 overexpresses EGFR) and CD33 minicells Pac (G12; A549 does not express CD33). Inhibition of tumor growth was evident in G11 mice and not in any other group including G12. On day 42, when the tumor volume was $400-500 mm 3 , the treatment of G12 mice was changed to EGFR minicells Pac which resulted in rapid tumor regression (p < 0.0003 at day 56 between G12 versus all groups).
(E) Safety of minicell-packaged i. were $400-500 mm 3 . This resulted in rapid tumor regression.
Since it is possible that anti-EGFR and anti-HER2/neu antibodies may elicit antiangiogenic effects (Petit et al., 1997; Izumi et al., 2002) , we carried out an HL-60 promyelocytic leukemia cell xenograft study in which minicells Dox were targeted to an HL-60 cell-surface marker CD33. Antibodies to this cell-surface marker are not known to exhibit antiangiogenic effects. Highly significant tumor growth inhibition was also observed in these mice ( Figure 5A ), suggesting that suppression of tumor growth (100 mg dox/dose) while G3 mice received DOXIL in a dose that provided the same amount of Dox (1 mg) as the G4 mice that were treated with EGFR minicells Dox . Highly significant tumor growth inhibition (p < 0.0001) was achieved in G2 and G4 mice, but not in G3.
(D) Dose-related effects of i.v. EGFR minicells Dox on tumor growth. Mice with MDA xenografts were treated with 10 6 , 10 7 , or 10 8 doses of EGFR minicells Dox ; each minicell dose carrying the amount of Dox indicated. Note that tumor volumes in all treated groups are significantly less by day 42 (p < 0.001) than in the untreated (tumor only) control animals. (E) Stability of the drug-packaged and BsAb-targeted minicells. Mice with MDA xenografts were treated with either freshly prepared or lyophilized and reconstituted EGFR minicells Dox . Both treatment groups (G2 and G3) showed similar significant degrees of tumor growth inhibition compared to the control group (G1), by day 25 (p < 0.0001).
by targeted, drug-packaged minicells is not dependent on antiangiogenic mechanisms. However, further work will be required to rule out the possibility that EGFR and HER2-targeted minicells have both direct and antiangiogenic effects. We also investigated if drug-packaged minicells could be used to treat SKOV3 ovarian cancer xenografts targeted via their overexpressed HER2/neu receptor. Additionally, in these studies minicells derived from both S. Typhimurium and E. coli minCDEÀ strains were tested for efficacy of drug delivery. The experimental groups received HER2 minicells Dox , and again, significant antitumor effect was seen in mice treated with either S. Typhimurium-or E. coli-derived HER2 minicells Dox ( Figure 5B ).
Comparison with Liposomal-Dox, Dose Response, and Minicell Stability
We compared the antitumor activity of liposomal-Dox (DOXIL) with that of EGFR minicells Dox . Mice with MDA xenografts were treated i.v. with DOXIL carrying high (100 mg) or low (1 mg) doses of Dox; the latter being the dose also given to animals treated with EGFR minicells Dox . Only the dose of DOXIL providing a 100-fold higher amount of Dox produced the same degree of tumor growth-inhibition as that seen with the EGFR minicells Dox treatment that provided only 1 mg of Dox ( Figure 5C ).
We also investigated the dose of targeted, drug-packaged minicells required to achieve a significant antitumor effect, using 10 6 , 10 7 , and 10 8 EGFR minicells Dox , each packaged with two different amounts of Dox and given i.v. to mice with MDA xenografts. Figure 5D shows that a dose of 10 8 EGFR minicells Dox was most effective in achieving tumor growth inhibition, whether carrying 85 ng or 660 ng of drug. The 10 7 and 10 6 doses of >EGFR minicells Dox were also effective, with the former being more effective than the latter. Thus, there is a clear relationship between minicell dose and antitumor efficacy. To determine the stability of the complete therapeutic entity, EGFR minicells Dox were lyophilized in an iso-osmotic cryoprotectant, trehalose, reconstituted in sterile physiological saline and injected i.v. into mice with MDA xenografts. Another group of mice were given freshly prepared EGFR minicells Dox . Both preparations were shown to be equally effective in stabilizing tumor growth ( Figure 5E ).
Minicell Biodistribution in Mice, Case Studies in NHL Dogs, and Minicell Safety in Pigs
The biodistribution of i.v.-administered minicells bearing 125 I-labeled BsAbs was studied in nude mice with MDA xenografts that overexpress EGFR. These studies revealed that at 2 hr posttreatment, $30% of the EGFR minicells were localized in the tumor, as compared to only $1.3% of nonspecifically targeted CMV minicells (Figure 6Aa ). In addition, in animals given radioiodinated BsAb alone ( EGFR BsAb or CMV BsAb), only $3 and 2.2%, respectively, of the radiolabel was localized in the tumor at 2 hr. By 6 (Figure 6Ab ) and 24 hr (Figure 6Ac ), $4.6% and $0.5%, respectively, of specifically targeted EGFR minicells remained in the tumors. These data suggest that in contrast to nonspecifically targeted CMV minicells, EGFR minicells are not only localized but are concentrated in the tumor microenvironment. This likely results from rapid extravasation of EGFR minicells from the circulation via the leaky vasculature of the tumor (passive targeting), followed by engagement of tumor cell-surface EGFRs (active targeting), adherence, and endocytosis. While nonspecifically targeted CMV minicells may also rapidly extravasate from the circulation, they are not retained in the tumors as they are unable to target EGFRs and are washed out after tumor isolation and extensive saline washing of the tissue.
Biodistribution of minicell-packaged drug was determined following i.v. administration of EGFR minicells Dox , nontargeted minicells Dox , or free Dox to nude mice with MDA xenografts (tumor volume between 140 and 170 mm 3 ). As shown in Figure 6B , at 6 hr, $30% of the Dox dose administered by the EGFR minicells Dox was found in the tumors, as compared to only $1% of free Dox and $0.34% of that in minicells Dox . Moreover, similar results were observed in animals with much larger tumors (400-600 mm 3 ), in which $28.1% of the Dox dose in EGFR minicells Dox was found in the tumors at 6 hr, as compared to only $0.21% of that in nontargeted, minicells Dox , and $1.8% for free Dox. Plasma concentration of Dox at both time points was undetectable. Thus, targeted minicell delivery provides at least a 30-fold enrichment in tumor drug delivery. At 6 hr, biodistribution to the liver and spleen was higher with the EGFR minicells Dox and minicells Dox compared to free Dox and showed a slow decrease by 24 hr. At 6 hr, the biodistribution to the lungs was also found to be higher with EGFR minicells Dox administration. However, it was rapidly cleared from this tissue, as was evident by the marked fall in lung Dox-levels at 24 hr. At 2 hr, minicell uptake in the liver (Figure 6Aa ) for EGFR minicells and CMV minicells was not significantly different (p = 0.095), suggesting that both types of minicells accumulate in the liver at similar levels. The data are further confirmed in Figure 6B where the Dox concentration in the liver at 6 hr and 24 hr post-i.v. administration of minicells Dox or EGFR minicells Dox is similar. The biodistribution studies reveal early localization of the minicells in the tumor and rapid clearance from all sites within 24 hr. These results are similar to other observations with noncoated nanoparticles (Jun et al., 2005) and is likely to be due to the passive targeting via the enhanced permeation and retention effect of the tumor-associated leaky vasculature.
The anticancer efficacy of the minicells was evaluated in two case studies in which dogs with advanced (stage 4) T cell non-Hodgkin's lymphoma (NHL) were treated i.v. with anti-canine-CD3 minicells Dox . One dog (4 kg) received a total of five doses over 35 days, and the other dog (40 kg) received seven doses over 48 days providing total amounts of Dox of 24 mg and 584 mg, respectively. Both dogs demonstrated marked tumor regression, as evident by highly significant reductions in lymph node size ( Figure 7A ), with the smaller dog also developing tumor lysis syndrome (hyperkalemia) by day 37 (data not shown).
The proinflammatory cytokines, TNFa ( Figure 7B ) and IL-6 (data not shown), did not increase in either dog despite repeated administration of CD3 minicells Dox . Surprisingly, anti-S. Typhimurium LPS titers also remained at background levels ( Figure 7C ), and evaluations of hematological indices, blood chemistries body weight, temperature, and urine analyses did not show any adverse changes with minicell administration (data not shown). The only mild potentially adverse response was a 0.5 C-1 C rise in temp postinjection. This was not sustained and had returned to normal by 4 hr postinjection.
We also evaluated the safety of i.v. administered minicells in three healthy pigs. Despite five successive i.v. doses of $5 3 10 9 minicells, the pigs did not show adverse effects, as determined from evaluations of hematological indices and blood chemistries, as well as by assessment of respiratory rate, food intake, growth, the levels of proinflammatory mediators (TNFa, IL-6; Figures  7D-7E) , and the acute phase reactant, haptoglobin ( Figure 7F ). Minor, variable increases in TNFa levels were observed at 1.5 hr after the administration of the third to fifth doses of minicells, which returned to baseline by 4-24 hr ( Figure 7D) . A weak serum anti-O antigen response was observed ( Figure 7G ) with the peak titer being evident after the second dose, which then decreased to even lower levels despite a further three doses. Postinjection, the pigs developed a minor fever but was not sustained and returned to normal within 2 hr.
DISCUSSION
We have developed a robust and versatile system for in vivo drug delivery using minicells, a bacterially-derived microreservoir-type carrier. These anucleate minicells ($400 nm diameter) can be readily produced in high yield from both Gram+ and GramÀ organisms and purified free of parental bacteria, membrane blebs, nucleic acids, cellular debris, and free endotoxin, using commercially available filters. Minicells are stable and can be targeted to cancer cells in vitro and in vivo with high specificity and can, thus, be delivered in high concentration in vivo without toxicity. This was evident by the lack of a febrile response, weight loss, or skin/fur changes, etc. in the murine xenograft model, as well as by the lack of any abnormalities in blood chemistries (electrolytes, renal, and hepatic function) in pigs given repeated i.v. doses. Minicells can package a range of anticancer chemotherapeutic drugs, such as doxorubicin, paclitaxel, irinotecan, 5-fluorouracil, cisplatin, carboplatin monastrol, and vinblastine despite their disparate structure, charge, hydrophobicity, and solubility. In contrast, attempts to EGFR minicells Dox (G3) to nude mice carrying MDA-MB-468 xenografts. Minicells (5 3 10 9 /dose) carrying $74 mg Dox were administered. Posttreatment, three mice from each group were euthanized at 6 hr and 24 hr. From each mouse, the tumor, spleen, liver, kidney, heart, and lung were excised and dox concentration was determined by HLPC and LC-MS/MS. At 6 hr EGFR minicells Dox delivered $30% of the total Dox dose administered to the tumor compared to that delivered with free Dox ($1%) or minicells Dox ($0.34%).
package these drugs in other DDSs, such as liposomes, has required specific and significant alterations to either the drug or vector, resulting in compromised potency. The phenomenon of solute movement into bacterial cells and the extrusion of noxious solutes from bacterial cells has been studied for over 3 decades and is well understood. Drug loading of minicells is likely by diffusion down a concentration gradient with entry via nonspecific porin channels (Nikaido, 1996 (Nikaido, , 2003 Poole, 2002) in the outer membrane. Detailed studies of porins have revealed charged residues within the channels resulting in a transversal electric field that separates polar and nonpolar solutes. Polar solutes are thought to be oriented in the field during permeation, which therefore becomes a fast onedimensional diffusion process (Schulz, 1993) . Nonspecific diffusion of hydrophobic solutes across the outer membrane is thought to occur through other channels such as the FadL family of outer membrane proteins (Van den Berg et al., 2004; Van den Berg, 2005) . We demonstrate that drug packaging in minicells is dependent on both the concentration of drug in the loading solution, and time of incubation (Figure 2A ). The finding of smooth saturable loading kinetics is consistent with a normal or ''Langmuir'' isotherm, suggesting drug loading via a limited number of uptake sites (Denyer and Maillard, 2002) . In addition to providing a barrier to solute entry, bacterial membranes contain a plethora of transport proteins involved in exporting solutes across their phospholipid bilayer membranes, against a concentration gradient (Piddock, 2006) . Thus, retention of drug in minicells, after loading, is likely due to the metabolic inactivity that results from their lack of bacterial genome.
We also demonstrated that bispecific ligands, such as BsAbs, can be linked to the surface of minicells via the cell-surface-exposed O-polysaccharide component of LPS. This enables their specific targeting to cancer cellsurface receptors, such as EGFR, HER2/neu, CD33, and CD3. Linkage to O-polysaccharide via the BsAbs is extremely robust; a factor that likely accounts, in part, for the efficiency of this cell-targeting approach. In addition, adhesion of the BsAb/minicell complex to cell-surface receptors appears to trigger its rapid and efficient endocytosis, with subsequent minicell degradation and liberation of drug into the cytosol and nucleus, where it exerts its cytotoxic effect. As a consequence, targeted minicell-mediated drug delivery resulted in highly significant inhibition and even regression of tumor growth in vivo in mice with human breast, ovarian, leukemia, or lung cancer xenografts. Nonspecific activation of hematopoietic cells by bacterial products was not sufficient for antitumor effects since in each xenograft study, nontargeted or nonspecifically targeted minicells with or without packaged drug did not result in antitumor effects. Additionally, rapid tumor regression was evident in two dogs diagnosed with NHL when treated with CD3 minicells Dox . This versatility of targeting and of tumor growth inhibition, therefore, are additional, very favorable features of the minicell drug-delivery technology. Other approaches to make anticancer mAbs more effective include conjugation with cell-killing payloads such as anticancer drugs (Saleh et al., 2000; Sievers et al., 2001 ) to generate armed antibodies. However, there is a limitation of four to ten drug molecules that can be conjugated to an antibody. Our results reveal that an unprecedented 1 million to 10 million drug molecules can be packaged within a minicell. Importantly, minicells were well tolerated with no adverse side effects or deaths in any of the actively-treated animals, despite repeat dosing. Given that the minicells are of bacterial origin, it is necessary to be cautious with parenteral administration since bacterial products are known to elicit potent inflammatory responses activated by Toll-like receptors (Shizuo and Takeda, 2004) . We have therefore developed a robust minicell purification procedure to eliminate free endotoxin and free bacterial components. Interestingly, in the two dogs and three pigs studied, only the latter demonstrated a very short lived and mild TNFa response. This contrasts with TNFa levels as high as 20,000 pg/ml after i.v. injection of 2 mg/kg LPS in pigs (Myers et al., 2003) . Interestingly, neither a TNFa response nor an increase in IL-6, another inflammatory cytokine, was observed in the tumor-bearing dogs despite repeat i.v. administration of high doses of minicells. Additionally, neither the pigs nor the dogs showed adverse effects in terms of their hematological indices, serum chemistries, food intake, or growth. Although our in vivo studies reveal weak immunogenicity of dominant minicell-surface exposed antigen, O-polysaccharide, and that repeat i.v. administration did not result in immune exclusion of subsequent doses, extensive evaluation of immunogenicity would be required to determine the nature of humoral and cellular immunity to the vehicle in both tumor-bearing and naive animals. Similarly, the safety data in pigs, although encouraging, must be considered preliminary and, prior to considering the minicell as a vector for human use, extensive toxicology, in vivo stability, etc. studies would be required. In recent times, excellent mouse models of human cancer have been developed and the above xenograft studies should be carried out in such models to provide greater insight regarding the potential and limitations of the minicell drug-delivery vector.
The most important feature of minicell drug delivery, however, is its ability to achieve inhibition/regression of tumor growth with delivery of amounts of drug that are markedly smaller than those required with systemic delivery of free drug. For example, with delivery of targeted minicells carrying Dox or Pac, tumor growth inhibition was significantly more marked in the xenograft models than with the administration of $1875-fold and $8000-fold higher amounts of their respective free drugs. Similarly, tumor lysis was observed in two NHL dogs despite receiving $25,000-fold and 10,270-fold less Dox via minicell administration than that normally administered as part of conventional combination therapy. This remarkable efficacy may be due to the specificity of drug delivery directly into the target tumor cell. Although case studies in the two dogs is very encouraging, the data are anectodal and further dog clinical trial studies would be required. Biodistribution studies in tumor-bearing mice showed that within 6 hr post-i.v. administration of EGFR minicells Dox , $30% of the injected dose of Dox was found in the tumor, a result that is consistent with the rapid and highly significant antitumor effects seen in the mouse and dog studies. At this early time point, significant Dox concentration was also observed in the spleen, liver, and lungs and is likely to reflect the excess minicells being taken up by professional phagocytic cells that predominate in these organs of the reticuloendothelial system since Dox-associated toxicity was not observed in these organs in the mouse and dog studies.
Nano-sized DDSs, such as immunoliposomes, are currently believed to affect tumor targeting by an initial passive process involving extravasation from the leaky vasculature (pore sizes 200-1.2 mm; Hobbs et al., 1998; Yuan et al., 1994) that supports the tumor microenvironment. This is followed by active targeting via cancer cell-surface receptor engagement and endocytosis (Mamot et al., 2003) . Although it has been shown that the abnormal tumor microenvironment is characterized by interstitial hypertension and that this phenomenon may limit access of anticancer antibody therapeutics, this does not appear to be an absolute barrier as is exemplified by immunoliposomes (Nielsen et al., 2002) and antibody conjugated to Quantum Dots (Gao et al., 2004) . Similar considerations are likely to also underlie the antitumor efficacy of minicell-based drug delivery. Moreover, although not specifically evaluated, the ability to administer very small yet targeted doses of chemotherapeutics should allow the therapeutic potential of even highly toxic agents to be realized, and/or the use of complex combination or sequential therapy.
EXPERIMENTAL PROCEDURES
Reagents and Minicell Generation Purification, Enumeration, and Lyophilization Detailed Supplemental Experimental Procedures (in the Supplemental Data available with this article online) describe bacterial strains, their growth, genomic DNA isolation, plasmids and oligonucleotides used (see Tables S1, S2 , and S3) and their purification. Also detailed online include minicell generation by chromosomal deletion of the minCDE genes in parental bacteria and minicell purification to homogeneity, for example, free of contaminating parent bacterial cells, cellular debris, bacterial blebs, and free endotoxin.
Bispecific Antibody Construction and Tumor Targeting Bispecific Antibody (BsAb) was constructed by linking an anti-S. Typhimurium O-antigen MAb (IgG1; Biodesign) and a mouse MAb directed against a cancer cell-surface receptor that is either antihuman EGFR (IgG2a; Calbiochem) or HER2/neu (IgG1; Serotec), or anticanine CD3 (IgG1; Serotec). Nonspecific BsAb carried an anti-CMV MAb (IgG2a; DakoCytomation). The two antibodies were crosslinked as detailed in the Supplemental Experimental Procedures online, via their Fc regions using purified recombinant protein A/G (Pierce Biotechnology), which results in BsAb as well as multimeric complexes. The BsAb was incubated with minicells for 1 hr at room temperature to enable BsAb binding to the minicell surface exposed O-polysaccharide. Excess unbound BsAb was removed by filtration through 0.2 mm filter (PALL). Approximately 5 mg of the BsAb complex was sufficient to saturate 10 9 minicells.
Cancer Cell Lines and Drug Packaging in Minicells
Chemotherapeutic drugs, Dox and Pac, were dissolved in sterile physiological saline and in 50:50 (v:v) Cremophor EL:ethanol, respectively (Sigma). Pac solution was diluted 1:5 in 0.9% saline immediately before injection. MDA-MB-468 breast, SKOV-3 ovarian, A549 lung, and HL-60 promyelocytic leukemia cancer cell lines (ATCC) were cultured in RPMI-1640 medium (Gibco) supplemented with 10% FBS, 2 mM Lglutamine, and 100 U/ml of both penicillin G and streptomycin. Liposomal-Dox (DOXIL) was purchased from Ortho Biotech. Purified minicells were packaged with chemotherapeutic drugs by incubating minicells at 37 C overnight with each drug, where the external loading concentration ranged from 10 to 400 mg/ml. Oregon Green 488-conjugated Pac and BODIPY FL-conjugated vinblastine were initially dissolved in ethanol and methanol, respectively, followed by dilution in BSG. Post-drug loading into minicells, excess drug was removed by Amicon stirred-cell ultrafiltration (Millipore; 300 kDa cut-off filter) with six washes of sterile BSG. Drug extraction from packaged minicells involved five cycles of vortexing and sonication in the presence of 97 mM HCl-isopropyl alcohol (HCl-IPA). The samples were then diluted in an equal volume of water and the five cycles were repeated. After centrifugation at 13,200 rpm for 5 min to pellet debris, the supernatants were harvested for drug quantitation, as detailed in the Supplemental Experimental Procedures online.
Electron and Fluorescence Microscopy of Minicells minCDEÀ mutant bacterial strains and purified minicells were processed for scanning and transmission EM using established protocols. Sections for TEM were visualized using a Hitachi H-7000 transmission electron microscope (ICPMR, Westmead Hospital, Sydney, Australia). Digital images were recorded using an AnalySis MegaView II widefield CCD camera. SEM specimens were examined using a Hitachi S-900 Field Emission scanning electron microscope. Samples were processed for immunogold-TEM using the freeze-substitution method (Riegman et al., 1988) and labeling minicells with anti-S. Typhimurium O-antigen (Factor 4, Group B specificity; Abbott Murex) mAb (1:200), followed by gold (10 nm)-conjugated secondary antibody. Samples were analyzed using a Philips CM-120 BioTWIN electron microscope at 80 kV. Images were captured onto type 4489 Kodak EM emulsion film. Fluorescence microscopy images of Minicells were captured using a Leica DMLB fluorescent microscope with an Olympus DP70 camera and DP controller/camera software. Pac fluorescence was viewed using the Leica GFP filter. Images showing the minicell-cancer cell interactions were captured using the IX81 confocal microscope (Olympus) and the CellR software.
Drug Quantitation Using HPLC, LC-MS, and ICP-MS Drugs extracted from minicells were quantitated based on HPLC-fluorescence peak and LC-MS/MS or ICP-MS (Inductively coupled plasma mass spectrometry) analyses as previously described for Dox (Zheng et al., 2001; Cummings, 1985) and Pac (Sharma et al., 1997; Larson et al., 2003) . HPLC analysis was performed on a Shimadzu 10AVP system incorporating a RF-10A XL fluorescence detector. Detailed extraction, analysis, and quantitation procedures for Dox, irinotecan, cisplatin, and Pac are provided in the Supplemental Experimental Procedures online.
In Vitro Cytotoxicity Assay and Tumor Xenograft Studies in Nude Mice
In vitro cytotoxicity was evaluated using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega), according to the manufacturer's instructions. Athymic (nu/nu) mice (4-6 weeks old) were purchased from the Animal Resources Centre, Perth, WA, and all animal experiments were performed in compliance with National Health and Medical Research Council, Australia, guidelines for the care and use of laboratory animals and with EnGeneIC Animal Ethics Committee approval. MDA-MB-468, SKOV-3, A549, and HL-60 human tumor cell lines were cultured and 1.5 3 10 6 cells in 50 ml serum-free media together with 50 ml growth-factor-reduced matrigel (BD Biosciences) were injected subcutaneously between the shoulder blades. Tumor volume (mm 3 ) was determined by measuring length (l) and width (w) and calculating volume (V = lw 2 /2) as described (Sun et al., 1999) .
Experimental and control treatments were carried out once the tumor volumes were between 50 and 80 mm 3 , at which time the tumor mass was clearly palpable and vascularized as determined following excision and microscopic observation of tumors. Mice were randomized to different groups prior to various treatments. All tumor volume measurements were performed by an investigator who was blinded to the treatments administered. Statistical analysis was performed by analysis of variance (ANOVA), with p < 0.05 being considered significant. minicells), respectively. Posttreatment, three mice from each group were euthanized at 6 and 24 hr and plasma and tissue was harvested, frozen, and lyophilized for extraction and determination of Dox concentration using ESI and Maldi and LC-MS/MS as detailed in the Supplemental Experimental Procedures online. Biodistribution of minicells was determined by radioiodinating anti-EGFR/anti-LPS or anti-CMV/ anti-LPS BsAbs prior to minicell surface O-polysaccharide attachment. The minicells were administered i.v. into nude mice bearing MDA-MB-468 xenografts. Five mice from each group were euthanized at 2, 6, and 24 hr posttreatment and tumor, spleen, liver, kidney, and lungs were excised from each mouse. The organs were washed in sterile saline and weighed, and radioactivity was determined using a Wallac Wizard 1470 Automatic Gamma Counter. Detailed methods are described in the Supplemental Experimental Procedures online. Two dogs with biopsy-proven T cell NHL were treated with CD3 minicells Dox , which targeted the canine CD3 T cell surface receptor as detailed in the Supplemental Experimental Procedures online. The dogs were treated at the Brisbane Veterinary Specialist Centre (Australia) with the owners' consent. The safety of minicells was determined in three large white Landrey 3 Durock pigs that were given $5 3 10 9 minicells i.v. through ear vein catheter as detailed in the Supplemental Experimental Procedures online. The study was carried out at the University of Sydney with the approval of the animal ethics committee.
Supplemental Data
The Supplemental Data include Supplemental Experimental Procedures and three supplemental tables and can be found with this article online at http://www.cancercell.org/cgi/content/full/11/5/431/DC1/.
